Glenmark gets US FDA nod for high blood pressure medicine
NEW DELHI: The US arm of Indian pharmaceutical major Glenmark PharmaceuticalsBSE 1.61 % has been granted final approval by the United States Food and Drug Administration (US FDA) for its generic version of Japanese drug maker Daiichi Sankyo’s Azor tablets. Azor—amlodipine and olmesartan medoxomil tablets—is used in the treatment of high blood pressure.
The market for Azor tablets (5 mg/20 mg, 5 mg/40 mg, 10 mg/20 mg, and 10 mg/40 mg) achieved annual sales of approximately $211.6 million for the 12 month period ended May 2017, said a release by GlenmarkBSE 1.61 % citing IMS Health sales data.
Glenmark’s current portfolio consists of 119 products authorized for distribution in the US and 66 Abbreviated New Drug Approvals (ANDAs) pending approval with the US FDA.
Share prices of Glenmark were up 1.53% at Rs 665.20 as of 9:45 am on Friday.